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Abstract
Background: Serum baseline tryptase (sBT) is a minor diagnostic criterion for systemic mastocytosis (SM) of undetermined
prognostic impact. We monitored sBT levels in indolent SM (ISM) patients and investigated its utility for predicting disease
behaviour and outcome.
Methods: In total 74 adult ISM patients who were followed for $48 months and received no cytoreductive therapy were
retrospectively studied. Patients were classified according to the pattern of evolution of sBT observed.
Results: Overall 16/74 (22%) cases had decreasing sBT levels, 48 (65%) patients showed increasing sBT levels and 10 (13%)
patients showed a fluctuating pattern. Patients with significantly increasing sBT (sBT slope $0.15) after 48 months of follow-
up showed a slightly greater rate of development of diffuse bone sclerosis (13% vs. 2%) and hepatomegaly plus
splenomegaly (16% vs. 5%), as well as a significantly greater frequency of multilineage vs. mast cells (MC)-restricted KIT
mutation (p = 0.01) together with a greater frequency of cases with progression of ISM to smouldering and aggressive SM
(p = 0.03), and a shorter progression-free survival (p = 0.03).
Conclusions: Monitoring of sBT in ISM patients is closely associated with poor prognosis disease features as well as with
disease progression, pointing out the need for a closer follow-up in ISM patients with progressively increasing sBT values.
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Introduction
Systemic mastocytosis (SM) includes a heterogeneous group of
disorders with increased mast cell (MC) numbers in different
organs and tissues [1,2]. The clonal nature of mastocytosis can be
established in virtually every case through demonstration of exon-
17 KIT mutations in MC [3,4], except for a rare subset of well-
differentiated SM patients [3–8]. From the clinical point of view,
the presence of multilineal KIT mutation in multiple bone marrow
(BM) hematopoietic lineages (e.g. myeloid and lymphoid BM cells)
represents in the largest series of ISM reported so far, the most
relevant prognostic factor of the disease, since it is able to identify
those patients at risk of progression to more advanced forms of the
disease [9].
Inside their cytoplasmic granules, MC contain tryptases (EC
3.4.21.59), a group of up to four distinct proteases (a-tryptase, b-
tryptase, d-tryptase and c-tryptase) which are also present in
smaller quantities in blood basophils [10]. Although all four forms
of tryptase are coded by genes localized in chromosome 16
[11,12]; they show a different pattern of expression in serum.
Thus, d-tryptase is not detected in serum and c-tryptase is not
released in a soluble form [13]. In turn, b-tryptase is stored in the
secretory granules of MC as an enzymatically active tetramer
forming a complex with heparin, which is released after MC
activation, whereas in vitro generation of a-(pro)tryptase is
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associated with the formation of enzymatically inactive tetramers
[14,15], and it is constitutively released from MC into the plasma
[16].
Currently, the only commercial technique available for the
quantification of total tryptase is ImmunoCAP Tryptase System
(Phadia, Uppsala, Sweden/Thermo Fisher Scientific Inc.); using
this test system, total tryptase values can be determined, although
the different isoforms of tryptases cannot be differentiated.
Increased total serum baseline tryptase (sBT) -recorded in the
absence of acute MC mediator release episodes- has long been
described in ISM [16,17], and sBT levels .20 ng/mL is a (minor)
diagnostic criterion for SM [1,2]. Overall, sBT levels in SM have
been associated with the total body MC burden [18], the extent of
BM involvement [1], diffuse bone sclerosis [8,9,19], and the
diagnostic subtype of the disease [20–22]. However, markedly
increased sBT have also been found in disease conditions other
than mastocytosis such as anaphylactic episodes [16,23] associated
or not with hymenoptera venom sting [24], clonal myeloid
malignancies [22], a subset of hypereosinophilic syndromes [25],
chronic urticaria [26] and advanced kidney disease [27–29].
Despite all the above, no study has been reported so far in which
the utility of sBT monitoring has been investigated in ISM patients
to determine its potential utility to predict for the behaviour of the
disease and patient outcome.
Here, we investigated the association between the pattern of
evolution of sBT levels during the first 48 months of follow-up in
ISM and adverse disease features, prognostic factors, as well as
progression of ISM to more advanced subtypes of the disease (e.g.
smouldering -SSM- and aggressive SM -ASM-).
Materials and Methods
This work was included in the research project RETICS
RD09/0076/00074, Hospital Virgen de la Salud Biobank (BioB-
HVS), Toledo, Spain; so, the approval was obtained from the
institutional review board ‘‘Comite´ E´tico de Investigacio´n Clı´nica
del Complejo Hospitalario de Toledo’’. It was completely
conducted in Spain, and all the adult participants as well as the
caretakers of the minors participants provided their written
informed consent to participate.
Patients
A total of 74 adults diagnosed with ISM who have been
followed by the Spanish Network on Mastocytosis (REMA)
between March 1995 and September 2012, were included in this
study. Inclusion criteria were: i) follow-up $48 months; ii) $3 sBT
determinations recorded in basal clinical situations during this
period; iii) absence of diffuse bone sclerosis at first sBT
determination;(19) iv) absence of cytoreductive or targeted thera-
pies that may had induced a decrease in sBT, and; v) data
available on KIT mutational status for highly-purified bone
marrow mast cells (BMMC), as well as purified cells from other
hematopoietic cell lineages. From the 74 patients analyzed, 33
(45%) were men and 41 (55%) women - median age at both the
first sBT determination and the first BM study of 41 years (range:
15–72 and 16–74 years, respectively)-. Diagnosis of ISM was
performed following previously established criteria for morphology
[30], histopathology and immunohistochemistry [31], flow
cytometry immunophenotyping [6,8,32–35], and molecular de-
tection of KIT mutations [3] following the World Health
Organization (WHO) criteria [1].
A clinical and physical work-up together with a routine
peripheral blood (PB) count and differential, routine biochemistry
and sBT (ImmunoCAP Tryptase System, Phadia, Uppsala,
Sweden/Thermo Fisher Scientific Inc.) were performed at referral
and thereafter, every 6 to 15 months. At the moment of closing
this study, all cases remained alive after a median follow-up of 113
months (range: 51–193 months), and a total of 787 sBT
determinations -median of 9 (range: 3–24) measurements per
patient- were performed. During follow-up, imaging studies
including abdominal ultrasonography and/or computed tomog-
raphy scan (CTscan), dual energy X-ray absorptiometry, skeletal
X-ray survey and/or magnetic resonance imaging (MRI) were
performed every 2 years, except in cases suspicious of having
clinical progression. Osteoporosis was defined following well-
established criteria [36] and the presence of bone sclerosis was
assessed by x-ray of bones, CTscan, and/or MRI. The presence of
B and C findings, as well as smouldering SM (SSM) as defined by
the WHO criteria [1] were recorded in each case.
Treatment was selected based on the intensity and/or severity
of symptoms. Different drugs (alone or in distinct combinations)
were used following previously described criteria [37]. Therapy
consisted of: i) the MC-stabilizer oral disodium cromolyn since the
referral; ii) scheduled or at demand sedating H1-antihistamines
(dexchlorpheniramine); iii) scheduled or at demand non-sedating
H1-antihistamines, depending on their availability along the study;
iv) scheduled H2-antihistamines, and; v) scheduled leukotriene
antagonists; vi) corticosteroids and epinephrine were only admin-
istered when strictly required. Other therapies used in selected
patients included non-steroidal anti-inflammatory agents for
refractory abdominal cramping and diarrhoea and, in non-
responders, short cycles of either low doses of prednisone
(0.3 mg/Kg/day) or oral budesonide (0.1 mg/Kg/day), with
progressively decreasing doses. In stress-induced anaphylaxis, a
psychiatric work-up was performed and adequate anxiolytic and/
or anti-depression therapy used. Intensive antimediator therapy
was defined by the use of scheduled disodium cromolyn plus any of
the other referred drugs to control MC-mediator related
symptoms. Cytoreductive therapy (interferon alpha-2b, hidrox-
yurea and cladribine) was prescribed in only 2 cases, following
progression to aggressive SM (ASM); further sBT determinations
performed in these two cases were excluded from the study.
Disease progression was defined as transformation of ISM into a
more aggressive WHO subtype of mastocytosis (e.g.SSM and
ASM) [1,2].
Statistical methods
K-means clustering analysis was used to classify ISM patients
into three groups according to the pattern of evolution of their sBT
levels during the first 48 months of follow-up: i) decreasing; ii)
fluctuating (increasing followed by decreasing sBT levels and vice
versa), and; iii) continuously increasing sBT. In addition, variation
in sBT was estimated by using a linear regression model
("y = ax+b") to establish the relationship between sBT levels ("y")
and the time of follow-up of the disease ("x"), and to calculate
time-associated changes in sBT levels ("a" being calculated as the
slope of the best linear fit), reflecting stable or decreasing versus
increasing sBT levels: slope of the best linear fit #0 (e.g. negative)
or .0 (e.g. positive), respectively.
The Kruskall Wallis and the Mann-Whitney U, or the x2 tests
were used to assess the statistical significance of differences
observed between groups for continuous and categorical variables,
respectively. For multivariate analyses (logistic regression), only
those variables that showed a statistically significant association in
the univariate study, were included in the model.
Optimal cut-off values for the slope of the best linear fit of
sequential sBT levels for predicting for multilineal KIT mutation
were calculated by receiver operating characteristic (ROC) curves.
Tryptase Role in Indolent Systemic Mastocytosis
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Progression-free survival curves were plotted according to the
method of Kaplan and Meier and compared by the log-rank test.
Statistical significance was set at p values ,0.05. For all statistical
analyses, the SPSS 17.0 (SPSS, Chicago, Ill), Excel 2010
(Microsoft) and MatLab R2010a (The MathWorks, Inc.) software
packages, were used.
Results
Pattern of evolution of disease features
According to the pattern of evolution of sBT levels during the
first 48 months of follow-up, 16 (22%) cases had decreasing sBT
levels, 10 (13%) patients showed a fluctuating pattern of sBT with
increasing (n = 5) or decreasing (n = 5) levels in the last analysis
performed, and the remaining 48 (65%) cases showed increasing
sBT levels, with either a continuous increase –20 (27%) cases- or
an initial increase followed by a tendency to stabilization –28
(38%) patients-. No significant differences were observed among
these three groups of patients as regards disease features at
diagnosis, except for a greater frequency of multilineal KIT
mutation (p = 0.02) and disease progression among cases with
increasing sBT levels (Table 1).
All cases with decreasing as well as fluctuating tryptase levels,
showed a sBT slope of,0.15; in more detail, cases with decreasing
sBT constantly displayed a negative slope while the group with a
fluctuating pattern included cases with both positive and negative
sBT slopes (5 and 3 cases, respectively). Conversely, most (31/48)
cases with increasing tryptase levels had a slope $0.15; among the
other 17 cases with increasing tryptase levels, 12 patients showed a
positive slope but with values lower than 0.15. (Table 1 and Table
2).
Upon regrouping ISM patients into cases presenting with
significantly increasing sBT levels $15% after 48 months of
follow-up (slope $0.15) vs. all other cases (sBT slope ,0.15) there
were no significant differences between the two patients groups as
regards their demographic and follow-up characteristics (Table 2)
except again, for a greater frequency of multilineal KIT mutation
(42% vs. 14%, p = 0.01%) and disease progression (13% vs. 0%,
p = 0.03) among cases with a higher sBT slope.
The frequency of MC-mediator related symptoms and the
usage of antimediator therapies were also similar in both groups
(Table 3). In addition, cases with a sBT slope $0.15 after 48
months of follow-up showed similar frequencies to those found
among the other patients (p.0.05) of osteoporosis as well as of
patchy and diffuse bone sclerosis, both at presentation and at the
end of follow-up (Table 2). Despite this, diffuse bone sclerosis
slightly developed more frequently among cases having a sBT
slope $0.15 (13% vs. 2% respectively, p.0.05). Similarly,
organomegalies (hepatomegaly plus splenomegaly) also developed
slightly more frequently among ISM cases with a sBT slope $0.15
(16% vs. 5%, p.0.05).
sBT monitoring and disease outcome
Overall, 4 cases developed SSM after a median follow-up of 49
months (range: 8–85 months). All four patients reached sBT values
.200 ng/mL after a median time of 57 months (range: 35–85
months), and they all had both sBT slopes $0.15 (p = 0.03; Table
2) and multilineal KIT mutation (p = 0.003). In addition, two of
them progressed to aggressive SM (ASM) after 56 and 94 months
of follow-up; both had an increasing sBT pattern with a sBT slope
of 12.44 and 0.98, respectively; furthermore, both cases developed
diffuse bone sclerosis (after 37 and 90 months) together with
hepatomegaly plus splenomegaly (after 54 and 90 months).
From a prognostic point of view, increasing sBT (slope $0.15)
together with the development of hepatomegaly plus splenomeg-
aly, were the only two informative parameters to predict for
Table 1. Demographic, clinical and laboratory characteristics of ISM patients (n = 74) grouped according to the pattern of
evolution of sBT after 48 months of follow-up.
sBT pattern
Variable DECREASING (n = 16) FLUCTUATING (n = 10) INCREASING (n = 48) p value
Female patients* 11 (69%) 5 (50%) 25 (52%) NS
Age at onset of the disease (years) 29 (7 – 52) 25 (0 – 43) 29 (12 – 72) NS
Age at 1st BM study (years) 43 (16 – 62) 33 (17 – 48) 42 (22 – 74) NS
Age at 1st sBT determination (years) 43 (16 – 62) 32 (17 – 48) 41 (15 – 72) NS
Time from disease onset to 1st BM study (months) 135 (27 – 463) 101 (45 – 210) 71 (0 – 281) NS
Time from disease onset to first sBT determination (months) 104 (27 – 463) 99 (45 – 210) 62 (0 – 88) NS
Time from 1st sBT determination to 1st BM study (months) 2 (0 – 71) 2 (0 – 12) 0 (0 – 91) NS
Time of follow-up (months) 118 (61 – 170) 90 (56 – 146) 117 (51 – 193) NS
First sBT determination (ng/mL) 39.7 (8.7 – 199) 22 (12.5 – 114) 26.6 (2.5 – 148) NS
Last sBT determination (ng/mL) 19.2 (7 – 183) 25.6 (10.7 – 70.8) 44 (7 – 1300) NS
sBT slope after 48 months of follow-up -0.23 (-2 – 0.04) 0.01 (-0.44 – 0.14) 0.25 (-0.09 – 12.4) ,0.001{
sBT slope $0.15 after 48 months of follow-up * 0 (0%) 0 (0%) 31 (65%) ,0.001
Multilineal KIT mutation* 0 (0%) 2 (20%) 17 (35%) 0.02
SSM* 0 (0%) 0 (0%) 4 (8%) NS
Progression to ASM * 0 (0%) 0 (0%) 2 (4%) NS
Results expressed as median values and range between brackets and *as number (percentage) of cases.
ASM, aggressive systemic mastocytosis; BM, bone marrow; NS, not statistically significant (p .0.05); sBT, serum baseline tryptase; SSM, smouldering systemic
mastocytosis.
{DP vs. FP, p = 0.008; DP vs. IP, p,0.001; FP vs. IP, p,0.001.
doi:10.1371/journal.pone.0076116.t001
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multilineal involvement of BM cells by the KIT mutation (p = 0.01,
and p = 0.009, respectively; Table 4); furthermore, multivariate
analysis confirmed that both parameters were independent and
that they provide the best combination of factors to predict for
multilineal KIT mutation with a 100% specificity (19% false-
negative and 0% false-positive results; Table 4). Similarly,
increasing sBT (slope $0.15) was a relevant predictor for
progression of ISM to more advanced forms of the disease such
as SSM and ASM, (p = 0.03; Figure 1).
Discussion
sBT is a useful biomarker for the diagnosis of SM including
ISM. However, few studies have analyzed the potential prognostic
value of sBT monitoring for the identification of ISM cases at risk
Table 2. Demographic, clinical and laboratory characteristics of ISM patients grouped according to the pattern of changes in sBT
levels (sBT slope) after 48 months of follow-up.
Variable sBT slope , 0.15 (n = 43) sBT slope $ 0.15 (n = 31) p value
Female patients 27 (63%) 14 (45%) NS
Age at onset of the disease (years) * 28 (0 – 61) 29 (12 – 72) NS
Age at 1st BM study (years) * 41 (16 – 63) 42 (22 – 74) NS
Age at 1st sBT determination (years) * 41 (16 – 63) 42 (15 – 72) NS
Time from disease onset to 1st BM study (months) * 84 (0 – 463) 71 (0 – 254) NS
Time from disease onset to 1st sBT determination (months) * 84 (0 – 463) 64 (0 – 254) NS
Time from 1st sBT determination to first BM study (months) * 1 (0 – 71) 0 (0 – 91) NS
Time of follow-up (months) * 118 (59 – 193) 105 (51 – 191) NS
Skin lesions 39 (91%) 28 (90%) NS
Multilineal KIT mutation 6 (14%) 13 (42%) 0.01
Percentage of BMMC*{ 0.07 (0.004 – 0.7) 0.1 (0.001 – 1.7) NS
Osteoporosis at first evaluation 4 (9%) 3 (10%) NS
Osteoporosis at the end of follow-up 6 (14%) 5 (16%) NS
Patchy bone sclerosis at the end of follow-up 2 (5%) 2 (6%) NS
Diffuse bone sclerosis at the end of follow-up 1 (2%) 4 (13%) NS
Organomegaly at first evaluation 0 (0%) 1 (3%)` NS
Organomegaly at the end of the follow-up 3 (7%)1 6 (19%)DD NS
Progression to SSM 0 (0%) 4 (13%) 0.03
Progression to ASM 0 (0%) 2 (6%) NS
Results expressed as number of cases from total cases in the group and percentage between brackets or *as median values and range between brackets.
ASM, aggressive systemic mastocytosis; BM, bone marrow; ISM, indolent systemic mastocytosis; NS, not statistically significant; MC, mast cells; sBT, serum baseline
tryptase; SSM, smouldering systemic mastocytosis.
{Assessed by flow cytometry.
`Splenomegaly.
1Hepatomegaly in one case, hepatomegaly plus splenomegaly in the other 2 patients.
DDSplenomegaly in one case, hepatomegaly plus splenomegaly in the other 5 patients.
doi:10.1371/journal.pone.0076116.t002
Table 3. Therapies used to control symptoms related to the release of mast-cell mediators in ISM patients grouped according to
the sBT slope (,0.15 vs. $0.15) after 48 months of follow-up.
sBT slope ,0.15 (n = 43) sBT slope $0.15 (n = 31)









Scheduled disodium cromolyn 7 (16%) 34 (79%) 38 (88%) 5 (16%) 27 (87%) 27 (87%)
Scheduled intensive antimediator therapy* 0 (0%) 12 (28%) 11 (26%) 0 (0%) 12 (39%) 12 (39%)
Antimediator therapy at demand{ 13 (30%) 9 (21%) 6 (14%) 8 (26%) 5 (16%) 6 (19%)
Epinephrine 3 (7%) 2 (5%) 1 (2%) 3 (10%) 1 (3%) 0 (0%)
Results are expressed as number of cases and percentage between brackets.
No statistically significant differences (p .0.05) were found between groups.
*Scheduled disodium cromolyn plus scheduled non-sedating or sedating H1 and/or H2 antihistamines, and/or leukotriene antagonists, and/or anxiolytic and/or anti-
depression therapy.
{Non-sedating or sedating H1 antihistamines and/or corticosteroids and/or epinephrine.
doi:10.1371/journal.pone.0076116.t003
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of disease progression. In the present study we investigated the
potential association between the pattern of evolution of sBT levels
during the first 48 months of follow-up and the features of the
disease both at diagnosis and during follow-up, including
progression to more aggressive forms of systemic mastocytosis.
Overall our results show that an increase in sBT levels after 48
months of follow-up with a slope $0.15 is associated with both the
presence of multilineal KIT mutation, and progression of ISM to
SSM (and to a less extent also ASM). Based on the cut-off value of
0.15 for the slope of sBT levels during the first 48 months of
follow-up, a major group of patients who systematically show KIT
mutation restricted to MC and stable disease together with a
smaller subset of ISM patients who more frequently show
multilineal KIT mutation (a parameter that has been associated
with a greater risk of disease progression) [9,38] were identified. In
addition to sBT, the presence of hepatomegaly plus splenomegaly
also emerged as an independent predictor for multilineal KIT
mutation, and only this subset of multilineal cases developed
diffuse bone sclerosis; these results suggest the existence of a close
association between these two features. In addition, sBT levels also
showed a significant impact on progression-free survival of ISM
patients, despite the still relatively limited follow-up. Of note, sBT
levels were systematically assessed in basal clinical conditions, to
avoid transiently elevated sBT levels associated to acute MC-
mediators release episodes, and no clear relationship was observed
between the use of antimediator therapy and the overall behaviour
of sBT (evaluated by the slope of sBT levels measured during the
first 48 months of follow-up). Despite this, we can not fully rule out
an impact of therapy (e.g. admisnistration of disodium cromolyn)
on decreasing MC-mediators release in individual patients,
particularly in those cases showing a negative sBT slope; further
investigations are required in this regard.
Previous reports have shown that multilineage involvement of
myeloid and/or lymphoid cells by the D816V KIT mutation is the
most powerful predictor for disease progression in ISM [9];
however, specific investigation of KIT mutation in multiple
individual myeloid and lymphoid compartments of maturing
BM hematopoietic cell lineages, is a technically demanding
approach which requires bone marrow sampling and is currently
not routinely performed in most diagnostic laboratories. In
addition, an immature immunophenotype of BMMC (defined by
the aberrant expression of CD25, usually in the absence of CD2,
associated with decreased expression of CD117, FceRI and
increased positivity for CD123, HLA-DQ, and HLA-DR) could
also predict for multilineal KIT mutation in ISM, regardless of the
diagnostic subtype of the disease [38]; however, such approach is
also frequently not available in many centres. Therefore, from a
practical point of view monitoring of sBT emerges as a potentially
interesting candidate surrogate marker for multilineage KIT
mutation among ISM with higher risk for progression to more
advanced forms of the disease.
Altogether, these observations strengthen the value and
robustness of sequential measurements of baseline serum tryptase
levels, for supporting the decision-making process regarding
further follow-up studies in ISM patients, and their time-points.
In this regard, our proposal for centres unable to determine the
pattern of KIT mutation in the different BM compartments of
hematopoietic cells, would be to perform an initial follow-up of
patients with ISM managed with conservative measures, by
monitoring sBT every 6 months during the first 4 years after
diagnosis, in order to estimate the sBT slope; in parallel, special
attention should also be paid to the development of hepatomegaly
plus splenomegaly and diffuse bone sclerosis (Figure 2). After 48
months of follow-up, every ISM patient could then be classified as
having a low vs. a high probability of carrying multilineal KIT
mutation, the latter being more prone to potentially undergo
progression to more aggressive forms of the disease. ISM patients
who are not suspicious of disease progression by routine criteria
and who have a sBT slope ,0.15 in the absence of hepatomegaly
plus splenomegaly, might undergo only an yearly control with
clinical and physical work-up together with a routine peripheral
blood count and differential, routine biochemistry and sBT, plus
an abdominal ultrasonography every 3 years (Figure 2). In
contrast, ISM patients with increasing sBT levels (slope $0.15),
should undergo peripheral blood analyses every 6 months and
abdominal imaging studies every year (Figure 2). Furthermore,
Table 4. Univariate and multivariate analysis of predictive factors for the presence of multilineal KIT mutation.
Univariate analysis Multivariate analysis
Predictive factor Patients, No. (%) RR (95% CI) p value HR (95% CI) p value
sBT slope $0.15 after 48 months of follow-up 13 (42%) 4.5 (1.5 – 13.6) 0.009 3.8 (1.2 – 12.3) 0.02
Hepatomegaly plus splenomegaly 5 (71%) 9.5 (1.7 – 54) 0.01 7.4 (1.2 – 45.8) 0.03
CI, confidence interval; HR, hazard ratio; RR, relative risk.
doi:10.1371/journal.pone.0076116.t004
Figure 1. Impact of the pattern of evolution of sBT levels (sBT
slope) in progression-free survival of ISM patients. PFS,
progression-free survival; sBT, serum basal tryptase.
doi:10.1371/journal.pone.0076116.g001
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bone imaging techniques should be performed during follow-up
for early identification of diffuse bone sclerosis, whenever, patients
have bone pain or sBT values $100 ng/mL in the absence of
other data suggesting progression to aggressive categories of the
disease.
In summary, our results show that serial measurements of sBT
during follow-up of ISM, is an easy accessible and powerful
predictor for multilineal KIT mutation and disease progression,
suggesting that serial sBT measurements could be of great help to
assess patient prognosis, particularly in those centers where
methods aimed at investigating the presence of the KIT mutation
in different compartments of BM hematopoietic cells are not
readily available We strongly recommend identificacion of ISM
cases at risk of disease progression, regardless of the experience of
individual centers. Only if this is done, adequate counseling,
follow-up and treatment can be applied to individual patients, to
avoid psychological stress, unnecessary periodical diagnostic tests
and administration of cytoreductive and/or targeted therapies in
the good-prognosis ISM patients.
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